Identification of a novelPARP14-TFE3gene fusion from 10-year-old FFPE tissue by RNA-seq

Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes

(2014) G. G. Malouf et al.   CLINICAL CANCER RESEARCH

An update on PARP inhibitors—moving to the adjuvant setting

(2014) Amir Sonnenblick et al.   Nature Reviews Clinical Oncology

Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers

(2014) Eric C. Kauffman et al.   Nature Reviews Urology

Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age and stage

(2013) Carla L Ellis et al.   MODERN PATHOLOGY

Comprehensive molecular characterization of clear cell renal cell carcinoma

(2013)   NATURE

A systematic analysis of the PARP protein family identifies new functions critical for cell physiology

(2013) Sejal Vyas et al.   Nature Communications

Translocation Renal Cell Carcinomas in Adults

(2012) Minghao Zhong et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Dual-color, Break-apart FISH Assay on Paraffin-embedded Tissues as an Adjunct to Diagnosis of Xp11 Translocation Renal Cell Carcinoma and Alveolar Soft Part Sarcoma

(2010) Minghao Zhong et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Current Treatment Protocols Have Eliminated the Prognostic Advantage of Type 1 Fusions in Ewing Sarcoma: A Report From the Children's Oncology Group

(2010) John A. van Doorninck et al.   JOURNAL OF CLINICAL ONCOLOGY

Translocation renal cell carcinoma

(2008) James I. Geller et al.   CANCER